- Open Access
Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells – evidence for a role in hepatocellular carcinoma growth in vivo
- Franziska Mußbach†1,
- Hendrik Ungefroren†2,
- Bernd Günther3,
- Kathrin Katenkamp4,
- Petra Henklein5,
- Martin Westermann6,
- Utz Settmacher1,
- Lennart Lenk7,
- Susanne Sebens7,
- Jörg P. Müller8,
- Frank-Dietmar Böhmer8 and
- Roland Kaufmann1Email author
© The Author(s). 2016
- Received: 8 February 2016
- Accepted: 18 July 2016
- Published: 29 July 2016
Previous studies have established that proteinase-activated receptor 2 (PAR2) promotes migration and invasion of hepatocellular carcinoma (HCC) cells, suggesting a role in HCC progression. Here, we assessed the impact of PAR2 in HCC stromal cells on HCC growth using LX-2 hepatic stellate cells (HSCs) and Hep3B cells as model.
PAR2 expression and function in LX-2 cells was analysed by RT-PCR, confocal immunofluorescence, electron microscopy, and [Ca2+]i measurements, respectively. The impact of LX-2-expressed PAR2 on tumour growth in vivo was monitored using HCC xenotransplantation experiments in SCID mice, in which HCC-like tumours were induced by coinjection of LX-2 cells and Hep3B cells. To characterise the effects of PAR2 activation in LX-2 cells, various signalling pathways were analysed by immunoblotting and proteome profiler arrays.
Following verification of functional PAR2 expression in LX-2 cells, in vivo studies showed that these cells promoted tumour growth and angiogenesis of HCC xenografts in mice. These effects were significantly reduced when F2RL1 (encoding PAR2) was downregulated by RNA interference (RNAi). In vitro studies confirmed these results demonstrating RNAi mediated inhibition of PAR2 attenuated Smad2/3 activation in response to TGF-β1 stimulation in LX-2 cells and blocked the pro-mitotic effect of LX-2 derived conditioned medium on Hep3B cells. Furthermore, PAR2 stimulation with trypsin or a PAR2-selective activating peptide (PAR2-AP) led to activation of different intracellular signalling pathways, an increased secretion of pro-angiogenic and pro-mitotic factors and proteinases, and an enhanced migration rate across a collagen-coated membrane barrier. Silencing F2RL1 by RNAi or pharmacological inhibition of Src, hepatocyte growth factor receptor (Met), platelet-derived growth factor receptor (PDGFR), p42/p44 mitogen activated protein kinase (MAPK) or matrix-metalloproteinases (MMPs) blocked PAR2-AP-induced migration.
PAR2 in HSCs plays a crucial role in promoting HCC growth presumably by mediating migration and secretion of pro-angiogenic and pro-mitotic factors. Therefore, PAR2 in stromal HSCs may have relevance as a therapeutic target of HCC.
- Proteinase-activated receptor 2
- Hepatocellular carcinoma
- Hepatic stellate cells
- Cell migration
- Receptor tyrosine kinase
- HCC xenograft
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the second most frequent cause of cancer-related death . Curative liver transplantation or resection is only possible in approximately 30 % of patients. For advanced HCC, the multi-kinase inhibitor sorafenib remains the only approved chemotherapy agent with survival benefits for advanced stage HCC patients. However, its use is limited to those with well-preserved liver function [2–4].
Up to 90 % of cases of HCC develop on the background of advanced liver fibrosis or cirrhosis, thus representing a typical inflammation-related cancer type. It is characterised by a tumour microenvironment where both tumour cells and stromal cells interact via secretion of cytokines, proteinases and other biological active factors. Key players in the organization of an optimal HCC stromal compartment are activated hepatic stellate cells (HSCs) [5, 6]. HSCs are characterised by high proliferation, pronounced matrix proteinase activity and secretion of extracellular matrix (ECM) proteins, as well as of factors including different proteases that aid in creating an immunosuppressive, angiogenic and tumour growth-promoting environment, and thereby critically contribute to HCC initiation and progression [7–18].
Proteinase-activated receptor 2 (PAR2)  belongs to a group of G protein-coupled receptors (for reviews see: [20–24]). It can be activated by serine proteinases including trypsin, neutrophil proteinase 3, mast cell tryptase, tissue factor(TF)/factor VIIa/factor Xa, human kallikrein-related peptidases and membrane-tethered serine proteinase-1/matriptase 1 as well as by parasite cysteine proteinases  and cathepsin S , but is insensitive to thrombin [21, 23]. Proteolytic cleavage of PAR2 at a specific domain in the extracellular NH2-terminus unmasks a “tethered ligand” that interacts with the body of the receptor. In addition, short synthetic peptides based on the proteolytically revealed receptor sequences (PAR2-activating peptides; PAR2-APs) and chemical modified peptide analogues, such as 2-furoyl-LIGRLO-NH2 [22, 27], can activate PAR2 in the absence of proteolytic cleavage. Beside a role in regulating physiological responses ranging from vasoregulation and cell growth to inflammation and nociception (reviewed in [20, 21, 23, 28, 29]) there is growing evidence for a function of PAR2 in tumours especially from epithelial origin [30–39]. In the setting of liver cancer, it could be demonstrated that PAR2 is expressed in HCC tissues, different HCC cell lines and primary HCC cultures established from surgically resected specimens of primary HCCs, where it stimulates liver carcinoma cell migration and invasion via different signalling pathways including [Ca2+]i mobilisation, Src, Met and p42/p44 MAPK [40, 41], and is involved in the regulation of CD47+ HCC stem cells (tumour-initiating cells, TIC) . In addition, TF/factor VIIa/PAR2-signalling cascade seems to be involved in the modulatory mechanisms of m-TOR-mediated autophagy in HCC . Overall, these data suggest a role for PAR2 in HCC progression.
At present no information is available about the impact of PAR2 in stromal cells for HCC development and progression. However, human HSCs have been shown to express PAR2 and upon its activation increase the release of collagen  and augment inflammatory and pro-fibrotic pathways through the induction of pro-inflammatory cytokines and extracellular matrix proteins . This indicates that PAR2 stimulates the activation, proliferation, collagen production, and TGF-β protein production by HSCs . Therefore, we specifically addressed this issue by evaluating the effect of PAR2 silencing in the HSC cell line LX-2  on tumour growth in a SCID mouse xenograft model, in which a HCC was induced by (co)injection of LX-2 cells and Hep3B liver carcinoma cells.
PAR2 knockdown inhibits tumour growth in a HCC-SCID mouse model
Having demonstrated both PAR2 expression and function, we went on to study the effect of PAR2 knockdown in LX-2 cells on the growth of tumour xenografts in vivo. For that purpose, suspensions of cells from the HCC cell line Hep3B and LX-2 cells (LX-2-wt) stably expressing a short hairpin (sh) RNA directed against PAR2 (LX-2-shPAR2) and LX-2 cells with a non-target control shRNA, (LX-2-shCo) were injected into the right flank of SCID mice. After 16 days, tumour formation was evaluated by macroscopic inspection, micro CT analysis and histochemical/immunohistochemical staining. While injection of LX-2-wt cells did not result in tumour development [Fig. 1d, (1)] and Hep3B cell injection alone yielded only small tumours (tumour volume < 3 mm3) in 2 out of 8 mice [Fig. 1d, (2)], simultaneous injection of Hep3B and LX-2-wt cells induced the development of large tumours (tumour volume approximately 50 mm3) [Fig. 1d, (3)]. Notably, the tumour promoting effect of LX-2 cells was significantly reduced when LX-2-shPAR2 cells were coinjected [Fig. 1d, (5)] but not with LX-2-shCo cells [Fig. 1d, (4)]. In Fig. 1e, representative micro CT images are shown for the tumours that developed under the skin of mice treated with Hep3B and LX-2-wt cells (3) and with simultaneous injection of Hep3B and LX-2-shCo cells (4) or LX-2-shPAR2 cells (5). Histochemical staining of tumour sections from experimental groups (2)-(5) by hematoxylin/eosin showed no gross differences and revealed histological features of a HCC with a trabecular growth pattern, central necrosis and pronounced inflammatory component (Fig. 1f). The epithelial nature of the tumours was confirmed by cytokeratin staining with the pan-keratin antibody MNF 116 .
To further characterise the inhibitory effect of F2RL1 silencing in LX-2 cells on tumour growth, immunohistochemical stainings of Ki67 and CD31 were performed to analyse tumour cell proliferation and tumour vascularization, respectively, both being hallmarks of cancer progression and tumour growth . As demonstrated in Fig. 1f, the number of Ki67-positive cells (Hep3B and LX-2 cells) was apparently higher in tumours induced by coinjection of Hep3B cells with LX-2-wt cells (or LX-2-shCo) than with PAR2 deficient LX-2 cells (quantification by manual counting revealed approximately 2.5-fold higher number of Ki67-positive cells, data not shown), strongly suggesting that the reduced tumour growth mediated by silencing F2RL1 in LX-2 cells may depend on diminished cell proliferation in the tumour microenvironment. Next, we assessed whether the reduced tumour growth with LX-2-shPAR2 cells correlated with changes in angiogenesis. Therefore, expression of endothelial marker CD31 in sections from tumours induced by coinjection of Hep3B cells with either wt, shCo or shPAR2 LX-2 cells were compared. As shown in Fig. 1f, PAR2 knockdown in LX-2 cells resulted in remarkably reduced immunostaining for CD31 indicating that LX-2-expressed PAR2 promoted angiogenesis. Overall these data suggest that PAR2 expression in HSCs promotes HCC growth by increasing cell proliferation and inducing angiogenesis.
PAR2 knockdown inhibits the pro-mitotic effect of LX-2 cell culture supernatants on Hep3B cells
PAR2 mediates activation of Src, Met, PDGFR and p42/44 MAPK and promotes TGF-β-induced Smad activation
TGF-β is overexpressed in HCC [50, 51] and considered to be a major factor promoting liver carcinogenesis. Specifically, TGF-β drives transformation of HSCs into myofibroblasts [52, 53] as well as their migration and invasion . PAR2 may enhance these pro-oncogenic effects by stimulating TGF-β gene expression and protein production in HSCs . However, based on recent data from our group , PAR2 may also promote TGF-β signaling in a more direct fashion in HSCs/LX-2 cells. Indeed, small interfering RNA (siRNA)-mediated depletion of PAR2 in LX-2 cells impaired the ability of TGF-β1 to induce C-terminal phosphorylation of Smad2 and Smad3, reflecting activation of the pathway, in response to TGF-β1 challenge (Fig. 3f).
Taken together, these data indicate that PAR2 activation stimulates a Src-Met/PDGFR-p42/p44 MAPK signalling axis in LX-2 cells while PAR2 protein expression is required for activation of TGF-β/Smad signalling.
PAR2 stimulation in LX-2 cells increases secretion of pro-angiogenic and pro-mitotic factors and proteinases
PAR2 activation increases migratory capabilities of LX-2 cells in a Src-, Met-, PDGFR-, p42/p44 MAPK- and MMP-dependent manner
It is well known that a migratory phenotype can be associated with epithelial-mesenchymal transition (EMT), which in turn involves morphological changes, such as lamellipodial protrusions and filopodial spikes . Therefore, scanning electron microscopy analyses on the various LX-2 cells were performed. Interestingly, treatment of LX-2 cells with PAR2-AP or trypsin induced the formation of filopodia spikes in a significantly larger number of cells when compared with non-stimulated controls (Fig. 5b).
To assess the contribution of the PAR2 activated signalling pathways (see Fig. 2) for LX-2 cell migration, we again performed inhibition studies with a battery of protein tyrosine kinase and MMP inhibitors. As shown in Fig. 5c, PP2, PHA 665752 and SU 11274 (another Met inhibitor), AG 1296, the MEK inhibitors PD 98059, SL 327 and U 0126, and the MMP inhibitor GM-6001 all inhibited the effect of PAR2-AP on migration of LX-2 cells. Overall, these data support the view that PAR2 activation increases the invasive capabilities of LX-2 cells via activation of Src, PDGFR, Met, p42/p44 MAPK and MMPs.
During the last years it became evident that PAR2 plays an important role in the development, progression and metastasis of tumours especially from epithelial origin [30–39, 60]. In case of HCC, studies have focussed on the function of PAR2 expressed by the tumour cells. This PAR-subtype is known to promote migration and invasion of HCC cells by stimulating various intracellular signalling systems including calcium mobilisation, reactive oxygen species, Met and p42/p44 MAPK [40, 41]. Moreover, PAR2 is involved in the regulation of CD47+ HCC stem cells, contributing to tumour initiation, self-renewal and metastasis . In addition, it could be shown that the TF/factor VIIa/PAR2-signalling cascade stimulates m-TOR signalling in liver carcinoma cells and reduces m-TOR-mediated autophagy induction in HepG2 xenografts in a SCID mouse model, suggesting a role in HCC progression .
Recent data indicated that also the stromal compartment plays a crucial role in HCC development and progression and provides an attractive target for HCC therapy [11, 14]. In the liver, HSCs, fibroblasts, myofibroblasts as well as immune and endothelial cells represent the major cell types of the hepatocyte stromal microenvironment. Among them, activated HSCs, beside their well-studied role in liver fibrosis and extracellular matrix remodeling , are discussed as a key driver for liver cancer development and progression [7–18]. HSC activation is regulated by complicated networks of numerous growth factors, proteinases, cytokines, integrins and their cognate receptors including the PAR family receptors [61, 62]. PAR2 has been shown to stimulate activation, proliferation, collagen synthesis and TGF-β production in HSCs and to promote experimental liver fibrosis [45, 63–65].
In this study, we provide for the first time evidence that PAR2 in HSCs stimulates HCC growth. This was concluded from the finding that F2RL1 knockdown in hepatic stellate LX-2 cells inhibited the growth-promoting effect of these cells in a HCC xenograft SCID mouse model, as demonstrated by significantly smaller volumes of the tumours established in mice by coinjection of Hep3B and LX-2 cells depleted of PAR2. In addition, immunohistochemical analyses of these tumours revealed lower indices for proliferation (reduced immunoreactivity of Ki67 in both Hep3B and LX-2 cells), and angiogenesis (reduced CD31 in endothelial cells). This suggests a promoting role for HSC-derived PAR2 in HCC growth through pro-proliferative, pro-angiogenic and possibly fibrotic effects on tumour and stromal cells in the HCC microenvironment. The pro-mitotic effect of HSC-derived PAR2 was subsequently shown in cell counting experiments with Hep3B cells stimulated with conditioned media from PAR2 depleted LX-2 cells. Of note, this growth promoting effect was specific to PAR2 and was not observed for the related PAR1. These data are in agreement with the in vivo data and show that HSCs act on tumour cells through the release of soluble mitogenic factors. We also observed that transfection of PAR2 siRNA decreased LX-2 cell numbers (data not shown), suggesting the possibility that HSC-derived PAR2 also contributes to tumour growth by promoting HSC proliferation in a cell-autonomous or auto-/paracrine manner. Given that activated HSCs are the major matrix producing cells in the liver, this may secondarily result in enhanced total matrix accumulation and eventually fibrosis.
It is now established that HSCs may facilitate HCC development, progression and metastasis by different processes including migration to the cancer site. More specifically, during cancer development activated HSCs infiltrate HCC stroma and peri-tumoural tissue and secrete substantial amounts of bioactive proteins  which may act either directly on the cancer cells or help to establish a microenvironment permissive for HCC progression. Migration of HSCs is known to be driven mainly by PDGF/PDGFR-dependent mechanisms [66–68], including a regulatory role for nitric oxide (NO) and the small GTPases, Rac1 and Rho [69, 70]. Notably, PAR2 induced the activation of PDGFR and Met following stimulation with PAR2-AP or trypsin, suggesting the possibility that PAR2 utilizes these pathways to drive the migratory capacity of LX-2 cells. The importance of this PAR2-PDGFR-Met crosstalk was further supported by the finding that the PAR2-mediated migration of LX-2 cells was blocked by AG 1296 and SU 11274/PHA 665752, respectively. In addition, we provided evidence for a role of Src and p42/p44 MAPK in PAR2-PDGFR/Met-induced signalling to PAR2-induced invasion in LX-2 cells, since this could be inhibited by PP2 and SL 327/U 0126, respectively, and stimulation of PAR2 with PAR2-AP or trypsin induced phosphorylation of Src and p42/p44 MAPK. Moreover, the PAR2-induced effect on p42/p44 MAPK could be blocked by AG 1296 and PHA 665752. These results also demonstrate that the PAR2-triggered phosphorylation of Src is upstream while p42/p44 MAPK is downstream of PDGFR and Met activation in LX-2 cells. Our results further indicate that, in addition to a Src-PDGFR/Met-p42/p44 MAPK signalling axis, MMP activity seems to be involved in PAR2-mediated invasive effect on LX-2 cells as concluded from the findings that LX-2 cells treated with PAR2-AP secrete MMPs 1, 3, 7, 13 and that the MMP inhibitor GM-6001 inhibited the effect of PAR2-AP and trypsin on LX-2 cell migration.
PAR2 activation augments inflammatory and pro-fibrotic pathways through the induction of genes encoding pro-inflammatory cytokines and extracellular matrix proteins . In line with this, our in vitro experiments with LX-2 cells showed that activated PAR2 not only stimulated cell migration but also the release of IL-8, uPA, cathepsins, MMPs and ADAMTS 1. All these factors are known to contribute to HCC initiation, growth and progression of HCC by degrading and remodeling the extracellular matrix and by stimulating angiogenesis and immunomodulation [71–77].
In addition to pro-inflammatory cytokines, TGF-β is considered a major factor promoting liver carcinogenesis. TGF-β1 and TGF-β2 are overexpressed in HCC [50, 51] and may also drive transformation of HSCs into myofibroblasts [52, 53] as well as their migration and invasion . Notably, HSCs and LX-2 cells are sensitive to TGF-β treatment [46, 61], and TGF-β gene expression and protein production in HSCs is stimulated by PAR2 . Prompted by recent observations in other cell types , we hypothesised that PAR2 expression is also required for TGF-β signaling in a cell-autonomous manner. To this end, depletion of PAR2 but not PAR1 from LX-2 cells inhibited the ability of TGF-β1 to activate Smad2 and Smad3. This suggests that HSC-derived PAR2, in addition to driving tumour cell and HSC proliferation may promote TGF-β sensitivity of HSCs and, as a consequence, matrix production.
Evidence for a crucial role for stromal cell-derived PAR2 in promoting primary tumour growth came also from mouse models for other solid and stroma-rich cancer types. PAR2 deficient mice (harbouring PAR2 deficient stromal cells) exhibit decreased tumour growth and metastasis in a spontaneous polyoma middle T (PyMT) breast cancer model . In a mouse model of pancreatic cancer, stromal PAR2 promoted primary tumour growth . In tumours resulting from B16 melanoma cells injected subcutaneously, PAR2 limited primary tumour growth . The role of stromal PAR2 in metastasis, however, appears to be strongly context-dependent. Stromal PAR2 limited lymph node metastasis in a spontaneous polyoma middle T (PyMT) breast cancer model  and in the pancreatic cancer mouse model  but enhanced spontaneous metastasis of B16 melanoma cells injected subcutaneously . Finally, PAR2 has been shown to play a critical role in stimulating tumour angiogenesis in the context of mammary carcinoma .
Our study provides novel insight into the function of PAR2 in HSCs, which may be involved in HCC growth and progression. PAR2 induces secretion of pro-angiogenic and pro-mitotic factors and proteinases, directly stimulates tumour cell growth in vitro through secreted factors and activates various signalling pathways (Src, Met, PDGFR, p42/p44 MAPK) being related to HSC growth and matrix production. It can be hypothesised that these mechanisms are of importance in the HCC microenvironment where both tumoural and stromal cells may produce PAR2-activating proteinases, like the kallikrein-related peptidases [82, 83] driving PAR2-mediated effects in HSCs on HCC growth.
Numerous studies convincingly demonstrate that HSCs play a critical role in HCC growth and progression [7–18]. From our data on LX-2 cells PAR2 may be concluded as a player in this scenario. This was supported by preliminary data demonstrating PAR2 function also in primary cultures of human HSCs (R.K. and H.U., unpublished observation). Since we used exclusively Hep3B cells as a HCC cellular model so far, analogous studies with other HCC cell lines and well-characterised primary HCC cultures are warranted to confirm the tumour-promoting function of PAR2 in HSCs.
Our data suggest that targeting PAR2 in HSCs may have potential for the treatment of this liver carcinoma.
Trypsin (EC 184.108.40.206; 14,700 U/mg) was obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany), and the selective Met receptor tyrosine kinase inhibitors PHA 665752 and SU 11274, the PDGFR inhibitor, tyrphostin AG 1296, the MAPK (MEK) inhibitors, PD 98059, U0126 and SL 327, the MMP inhibitor GM-6001 (galardin) and the Src inhibitor PP2 were from Calbiochem/Merck Biosciences (Bad Soden, Germany). Trypan blue exclusion tests confirmed that these inhibitors did not impair cell viability of LX-2 cells (approx. 95 % viability after treatment for 24 h, data not shown). Rabbit polyclonal anti-phospho-Met-antibody [pYpYpY1230/1234/1235] and rabbit polyclonal anti-phospho-PDGFR-α [Tyr849]/PDGFR-β [Tyr857] were from Life Technologies GmbH (Darmstadt, Germany), a phosphospecific monoclonal antibody to p42/p44 MAPK, and rabbit polyclonal anti-PDGFR-α antibody, C-20, a polyclonal anti-p42/p44 MAPK antibody, a polyclonal anti- Met (C12) antibody and a mouse monoclonal anti-PAR2 antibody, SAM 11, were from Santa Cruz Biotechnology, Inc., Heidelberg, Germany. A polyclonal rabbit anti-phospho-Smad2 (S465/S467)/Smad3 (S423/S425) antibody (#AB3226) was from R&D Systems (Wiesbaden, Germany) and an anti-β-actin antibody from Sigma. A rabbit polyclonal anti-Src [pY418] antibody was from BioSource Europe, S.A., Belgium and a monoclonal anti-Src antibody was from Upstate Biotechnology, Lake Placid, NY, USA. As secondary antibodies goat anti rabbit IgG-HRP-conjugated, goat anti mouse IgG-HRP-conjugated and goat anti rabbit IgG-FITC conjugated (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) were used. The PAR2 antagonist GB 88 (5-isoxazoyl-Cha-Ile-spiroindene-1,4-piperidine), which selectively blocks PAR2 calcium signalling  was a kind gift from Dr. David Fairlie, (Institute for Molecular Biosciences, University of Adelaide, Australia).
The PAR1-selective peptide, TFLLRN-NH2, PAR2-AP, 2-furoyl-LIGRLO-NH2 and PAR2-RP 2-furoyl-OLRGIL-NH2, were synthesised by Fmoc strategy on an ABI-Peptide-Synthesizer 433A using H-Rink Amide ChemMatrix®resin (capacity 0.47 respectively 0.52 mmol/g; PCAS BioMatrix Inc, Canada). The furoyl-group was coupled manually with 5 equivalents of acid. The cleavage of the peptides from resin was performed with trifluoroacetic acid, 5.0 % H2O und 3.0 % triisopropylsilane. The peptides were precipitated by diethylether and lyophilized. Crude synthetic peptides were purified using preparative HPLC on a 30 × 250 mm Kromasil C18-column with a flow rate of 40 ml per minute under standard conditions (buffer A: 0.2 % TFA in water, buffer B: 0.2 % TFA in water:acetonitrile, 1:4). The purified peptides were dried by lyophilization and characterised by analytical HPLC and mass spec analysis on a Voyager-DE PRO workstation.
LX-2 cells (gift from Prof. Scott Friedman, Mount Sinai School of Medicine, New York, USA) were cultured in Dulbeccos modified Eagles’s medium (DMEM) supplemented with 2.0 % fetal calf serum at 37 °C in a humidified atmosphere of 5.0 % CO2. The medium was changed every 2–3 days. Hep3B HCC cells (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, ACC 325) were routinely cultured in RPMI-1640 supplemented with 10 % fetal calf serum at 37 °C in a humidified atmosphere of 5.0 % CO2. The medium was changed every 2–3 days and for subculturing cells were trypsinised. Since trypsin itself activates PAR2 the subcultured cells were re-fed sufficiently to remove all traces of trypsin.
[Ca2+]i was measured in single cells with fluo-4, a fluorescence indicator for free Ca2+. Cells were grown on Lab-Tek™ chambered borosilicate cover glass (Nunc GmbH & Co. KG, Wiesbaden, Germany) and washed twice with HEPES buffer (pH 7.4) containing 10 mM HEPES, 145 mM NaCl, 0.5 mM Na2HPO4, 6.0 mM glucose, 1.0 mM MgSO4, 1.5 mM CaCl2. Cells were incubated for 15 min at 37 °C in the same buffer containing 0.5 μM fluo-4 acetoxymethylester (fluo-4-AM). After loading, the cells were washed twice and reincubated in HEPES buffer. For calcium measurement in single cells, an inverted confocal laser scanning microscope (LSM 510, Carl Zeiss, Göttingen, Germany) was used. Fluorescence images were collected by using the 488 nm argon ion laser line and a 505 nm long pass filter. All fluorescence measurements were made from subconfluent areas of the dishes, enabling the ready identification of individual cells. Image data were analysed using the Carl Zeiss AIM software Version 4.2. A selected image in each image set was used as a template for designating each cell as a region of interest.
The intracellular calcium concentration was calculated using the equation [Ca2+]i = 345 (F-Fmin)/(Fmax-F) . The Ca2+ affinity of fluo-4 (Kd) is 345 nM . Fmax was obtained by addition of 10 μM ionomycin (+6.0 mM CaCl2), Fmin by addition of 10 mM ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA). The average of calcium data obtained by measuring 20 cells was used for calibration.
Reverse Transcription (RT)-PCR analysis
Total RNA was extracted from 1 × 107 LX-2 cells (RNeasy ® Mini Kit, Qiagen GmbH, Hilden, Germany), and for RT-PCR analysis the Reverse Transcription System (Cat. No. A 3500) from Promega Corporation (Madison, WI, USA) was used. For PCR amplification the following primer pairs were used: forward primer: 5’-TGGATGAGTTTTCTGCATCTGTCC-3’ and 5’-CGTGATGTTCAGGGCAGGAATG-3’. The primers were constructed to generate a fragment of 490 bp for PAR2. PCR amplification was performed with Taq polymerase for 32 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s, and, finally 72 °C for 5 min . Amplified samples were electrophoresed on a 2.0 % agarose gel containing 0.2 μg/ml SybrGreen and visualized under UV transillumination. In addition, PCR products for PAR2 of LX-2 cells were purified and DNA sequences were determined by 4base lab GmbH, Reutlingen (Germany).
Transient transfection of LX-2 cells with PAR2 siRNA and TGF-β stimulation
For transient silencing of F2RL1, LX-2 cells seeded on day 1 (2.8 × 105/6-well) underwent two rounds of a 4-h transfection on days 2 and 3 with 50 nM of siRNA to PAR2 (Invitrogen) and Lipofectamine 2000 transfection reagent (Life Technologies). As control, a siRNA to PAR1 or a universal control siRNA (both from Life Technologies) was transfected in parallel. Successful knockdown of PAR2 and PAR1 expression was verified by quantitative real-time (RT)-PCR as outlined elsewhere  (data not shown). For sequence information on siRNAs and PCR primers see . Forty-eight hours after the second transfection, supernatants to be used for Hep3B proliferation assays (see below) were collected, centrifuged briefly to remove dead cells and cellular debris and stored frozen until use. The remaining LX-2 cells were stimulated for 0.5 h with TGF-β1 (10 ng/ml, ReliaTech, Wolfenbüttel, Germany) in normal growth medium followed by lysis in RIPA buffer containing protease (Boehringer Complete, PMSF)/phosphatase (NaF, sodium orthovanadate) inhibitors and phosphoimmunoblotting for Smad2/3 (see below).
For testing the effect of PAR2 silencing on cell viability, cells were seeded into 24-well plates and after treatment with the respective siRNA the viable cells were counted by trypan blue dye exclusion test.
Generation of LX-2 cells with stable expression of PAR2 small hairpin RNA (shRNA)
Plasmid pLKO.1 vectors encoding shRNA constructs targeting human PAR2 and plasmid pLKO.1 encoding a non-targeting control shRNA were obtained from Sigma (MISSION® shRNA lentivirus-mediated transduction system, SHCLNG-NM_005242).
To generate lentiviral particles, HEK293T cells were maintained in DMEM (Biochrom) supplemented with 10 % FCS. The cells were transiently transfected with the pLKO.1-derived plasmids in combination with pRev, pEnv-VSV-G and pMDLg using polyethyleneimine. After 12, 24 and 48 h, media containing the retrovirus particles were collected. LX-2 cells were infected three times with the particles in the presence of 8.0 μg/ml polybrene. Forty-eight hours after transduction, transduced cells were selected with 2.0 μg/ml puromycin. The efficiency of the knockdown was assessed by quantitative real-time RT-PCR and by calcium measurements. PCR amplification was performed with Maxima Hot Start Taq DNA Polymerase for 40 cycles at 94 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s and finally 72 °C for 5 min. Primers were forward: 5’-TGGATGAGTTTTCTGCATCTGTCC-3’, and reverse: 5’-CGTGATGTTCAGGGCAGGAATG-3’. The qPCR was performed on a MasterCycler RealPlex4 (Eppendorf, Hamburg, Germany). All values for PAR2 expression were normalized to those for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the same sample.
For calcium measurements the effect of trypsin and the PAR2-AP, 2-furoyl-LIGRLO-NH2, on [Ca2+]i mobilisation in PAR2 knockdown-LX-2 cells was investigated as described above.
The expression of PAR2 on protein level was established using the monoclonal anti-PAR2 antibody SAM-11, generated against a peptide representing amino acids 37SLIGKVDGTSHVTG50 of human PAR2 (Santa Cruz Biotechnology). This antibody has been validated for western blot and immunohistochemical/flow cytometry procedures [88, 89]. LX-2 cells, grown on glass coverslips were washed in TBS containing 4.0 % Tween 20, fixed with 2.0 % paraformaldehyde in 0.1 M cacodylate buffer + 4.0 % Tween 20 and washed with 0,1 M glycine buffer (pH 9.0) as well as with TBS + 4.0 % Tween 20. Thereafter, the cells were treated with 10 mM citrate buffer (pH 6.0) in a microwave oven (Miele Supratronic, M 752) at 80 W, washed in 10 mM Tris/EDTA (1.0 mM) buffer (pH 9.0), followed by rinsing in TBS. Then, cells were covered with the secondary antibody (FITC-conjugated anti-mouse IgG). Control experiments were carried out under omission of the primary anti-PAR2 antibody or by using mouse IgG2a instead of SAM-11. LX-2 cells were analysed using the confocal laser scanning microscope LSM 510 Meta (Carl Zeiss). Fluorescence images were collected by using the 488 nm argon ion laser line.
Field emission scanning electron microscopy (FESEM)
LX-2 cells grown on glass cover slips were washed three times with PBS, prefixed with 0.1 % glutaraldehyde in PBS and washed four times in PBS. The cells were incubated 30 min in labeling blocking buffer (LBB): 1.0 % BSA, 0.5 % gelatin, 0.005 % Tween-20 in PBS, pH 7.2). For PAR2 immunolabeling, monoclonal anti-PAR2 antibody, SAM-11, diluted 1:25 in LBB, and as secondary antibody, a goat anti-mouse IgG coupled with 20 nm gold particles (British Biocell International, Cardiff, UK; 1:50) were used. After immunolabeling, the cells were rinsed in PBS three times and fixed with 2.5 % glutaraldehyde in PBS for 30 min. After three washings in PBS the cells were dehydrated in rising ethanol concentrations followed by critical point drying and carbon coating in a BAL-TEC SCD 005 Sputter Coater (BAL-TEC, Balzers, Liechtenstein). The cells were examined in a LEO 1530 Gemini field emission scanning electron microscope (Carl Zeiss) at 5 kV acceleration voltage and a working distance of 7 mm using a Centaurus scintillation type backscatter electron detector (K.E. Developments, UK).
Analysis of plasma membrane filopodial structures
LX-2 cells were grown on glass coverslips. After incubation with PAR2-AP for 4 h, the cells were fixed with 2.5 % glutaraldehyde and subsequently dehydrated as described for detection of PAR2 immunolabeling. The cells were sputter coated with gold and examined in a LEO 1450 VP scanning electron microscope (Carl Zeiss) at 10 kV acceleration voltage and a working distance of 7 mm. In this study, the cells were scored as positive or negative for filopodial spikes. Filopodia-positive cells were defined as having more than 10 thin processes beyond the cellular edge of the plasma membrane . Quantitative analyses were performed in a blinded manner from 100 individual cells per each group and from three experimental preparations.
Preparation of cell lysates
The cells were collected by centrifugation at 1000 × g for 5 min (4 °C), washed with PBS containing bacitracin (100 μg/ml), PMSF (0.1 mM), pepstatin A (1.0 μg/ml) and leupeptin (2.0 μg/ml), pH 7.4, and centrifuged again. The pellet was treated with lysis buffer (PBS, containing 1.0 % (v/v) Triton X-100, 0.5 % (w/v) deoxycholate and 0.1 % (w/v) SDS for 30 min at 4 °C, resuspended and centrifuged at 30000 × g for 15 min (4 °C).
Protein was determined using the DC Protein Assay System from BioRad Laboratories according to the manufacturer instructions.
Analysis of Src, Met, PDGFR, p42/p44 MAPK and Smad2/3 phosphorylation
Immunoprecipitation (IP) and Western blotting
For IP, cleared cell lysates normalized for protein content were treated with 2.0 μg anti-PDGFR antibody for 2–3 h, followed by 20 μl protein A-Sepharose beads overnight at 4 °C. Beads were collected by centrifugation, washed three times with lysis buffer containing 2.0 μg/ml leupeptin, 1.0 μg/ml pepstatin A, 100 μg/ml PMSF, 100 μg/ml aprotinin, 1.0 mM Na3VO4 and 1.0 mM NaF. Ten μl Roti®-Load were added to the beads and the samples were heated for 5 min at 95 °C.
Proteins of cell lysates (Src, Met, p42/p44 MAPK and Smad 2/3 detection) or immunoprecipitates (PDGFR detection) were subjected to 10 % SDS-PAGE and transferred to nitrocellulose membranes (BioRad Laboratories). After blocking in 1.0 % BSA/1.0 % skimmed milk for 1 h, the nitrocellulose strips were incubated overnight with the respective first antibody. Strips were washed two times with 0.05 % Tween 20 washing buffer, incubated for 45 min with the respective secondary antibody conjugated to horseradish peroxidase and washed again two times as described above. In all experiments, the immunoblots were stripped and reprobed with antibodies to total protein to confirm equal protein loading. Secondary antibodies were detected by using the chemiluminescence (ECL) Western blotting detection system (Amersham) and exposure to Kodak X-Omat films.
Immunoreactive bands for phosphorylated forms of Src (p-Src), Met (p-Met), PDGFR (p-PDGFR),p42/p44 MAPK (p-p42/p44 MAPK), Smad2 and Smad3 (p-Smad2/3) as well as Src (t-Src), total Met (t-Met), total PDGFR (t-PDGFR), total p42/p44 MAPK (t-p42/p44 MAPK), and β-actin were quantified using the image processing program Image J 1.43 (National Institutes of Health, Bethesda, Maryland, USA).
Proteome profiler arrays
LX-2 cells, serum-starved for 17 h, were treated with PAR2-AP, 2-furoyl-LIGRLO-NH2, trypsin or vehicle for 24 h. For determination of the relative levels of different proteins in the supernatant, proteome profiler arrays [Human Angiogenesis Array Kit, Catalog Number ARY007 (allows to simultaneously detect simultaneously the relative changes of 55 angiogenesis-associated cytokines: Activin A, ADAMTS, Angiogenin, Angiopoietin-1, Angiopoietin-2, Angiostatin/Plasminogen, Amphiregulin, Artemin, Tissue Factor/Factor III, CXCL16, DPPIV/CD26, EGF, EG-VEGF Endoglin/CD105, Endostatin/Collagen XVIII, Endothelin, FGF acidic, FGF basic, FGF-4, FGF-7/KGF, GDNF, GM-CSF, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IL-1 beta, CXCL8/IL-8, LAP (TGF-beta 1), Leptin, CCL2/MCP-1, CCL3/MIP-1 alpha, MMP-8, MMP-9, NRG1-beta 1, Pentraxin 3, PD-ECGF, PDGF-AA, PDGF-AB/PDGF-BB, Persephin, CXCL4/PF4, PlGF, Prolactin, Serpin B5/Maspin, Serpin E1/PAI-1, Serpin F1/PEDF, TIMP-1, TIMP-4, Thrombospondin-1, Thrombospondin-2, uPA, Vasohibin, VEGF, VEGF-C) and Human Protease Array Kit, ARY021 (allows to simultaneously detect the relative changes of 35 proteinases: ADAM8, Cathepsin X/Z/P, MMP-7, ADAM9, DPPIV/CD26, MMP-8, ADAMTS, Kallikrein 3/PSA, MMP-9, ADAMTS13, Kallikrein 5, MMP-10, Cathepsin A, Kallikrein 6, MMP-12, Cathepsin B, Kallikrein 7, MMP-13, Cathepsin C/DPPI, Kallikrein 10, Neprilysin/CD10, Cathepsin D, Kallikrein 11, Presenilin-1, Cathepsin E, Kallikrein 13,Proprotein, Convertase 9, Cathepsin L, MMP-1, Proteinase 3, Cathepsin S, MMP-2, uPA/Urokinase, Cathepsin V, MMP-3) R&D Systems, Minneapolis, MN 55413, USA] were used according to the manufacturer’s instructions. Briefly, nitrocellulose membranes were blocked for 1 h and then incubated with 500 μl of supernatant (24 h after treatment with PAR2-AP or vehicle) overnight at 4 °C. After washing, the membranes were incubated with the detection antibody cocktail for 2 h and streptavidin–HRP for 30 min. For data evaluation, the membranes were exposed to chemiluminescent reagents (ECL Plus Western Blotting Detection System; Amersham) and finally to X-ray films for 30 s. The developed films were scanned and the average pixel density of the positive signals was analysed using the analysis software Image J 1.43 (National Institutes of Health, Bethesda, Maryland, USA). All images from the arrays were normalized by subtracting the background and inverted to eliminate the background differences. To measure the pixel density, a fixed size rectangular box was generated around each dot blot/band and the pixel density was measured. The same sized rectangular box was used for all bands in all arrays performed. For analysis, the pixel densities of the negative control on each array were subtracted from the pixel densities obtained from each band on the array. The data was further converted and normalized into fold change in expression by dividing the pixel densities of each band by the average pixel densities of the Streptavidin-HRP reference spots (R) located at the three corners of each array.
Stimulation of Hep3B cells with LX-2 cell conditioned media and cell counting
Hep3B cells were seeded in 48-well plates (2 × 104/well). On the next day, the growth medium was removed and replaced by 500 μl of cleared culture supernatant conditioned for 48 h by LX-2 cells transfected with either control siRNA, PAR1 siRNA or PAR2 siRNA (see above: “Transient transfection of LX-2 cells with PAR2 siRNA and TGF-β stimulation”). Following incubation with the LX-2 conditioned media for 72 h, the medium was removed, centrifuged to collect non-adherent cells and the resuspended pellets combined with the detached adherent cells from the respective well. Then, viable and dead cells were counted by trypan blue dye exclusion test.
Cell migration assay
LX-2 cell migration was measured using a 48-well boyden-chamber (NeuroProbe, Inc., Gaithersburg MD, USA). 51 μl of the cell suspension (4 × 104 cells in RPMI-1640) with or without inhibitor were placed in each upper chamber well and 27 μl of cell culture medium containing the chemoattractant or vehicle in each lower well. Then, incubation for 6 h at 37 °C in a humidified incubator with 5.0 % CO2 was performed to allow cell migration through a porous polycarbonate filter (6.5 mm in diameter, 8.0 μm pore size) precoated with collagen (0.35 %). After the incubation period, the filter was removed, and its upper side was wiped gently with a cotton tip swab to remove non-migrated cells. The migrated cells were fixed on the lower surface of the membrane with 96 % ethanol, stained with Giemsa solution, and counted under a Zeiss Axiolab microscope. Data were acquired from three independent experiments, involving octuplicate measurements for each condition.
Estimation of cell viability
For testing the effect of inhibitors on LX-2 cell viability, cells were seeded into 24-well plates. Following treatment with the respective inhibitor for 24 h, viable and non-viable cells were distinguished by trypan blue dye exclusion method and counted manually. In addition, this test was used to monitor the viability of LX-2 cells from cultures used for animal experiments and that of Hep3B cells incubated with LX-2 culture supernatants.
Five to six week-old, male SCID mice (BALB/cJHAN®-Prkdc scid ) were purchased from Harlan Laboratories Ltd. (Venray, Germany) and were handled under governmental and institutional rules and regulations after approval by the respective authorities. Animals were housed under specific pathogen-free conditions with a 14 h light/12 h dark cycle and received food and tap water ad libitum.
Mice were randomised into 5 groups, each group was consisted of 8 animals. Different cell preparations (cell viability > 95 %, estimated with trypan blue exclusion test) were suspended in 200 μl DMEM and subcutaneously injected at the right flank of the mice under general anesthesia using diethylether [group 1: 5 × 105 LX-2 (wild type) cells, group 2: 105 Hep3B cells; group 3: 105 Hep3B cells plus 5 × 105 LX-2 (wild type) cells, group 4: 105 Hep3B cells plus 5 × 105 LX-2 (non-target control gene knockdown) cells, group 5: 105 Hep3B cells plus 5 × 105 LX-2 (PAR2 gene knockdown) cells]. Sixteen days after xenotransplantation, micro-computed tomography (micro CT) analyses were performed under isofluorane anesthesia (CT Imaging, Erlangen, Germany). For 3D reconstruction of the tumours the software “Imalytics” (Philips GmbH, Aachen, Germany) was used. Subsequently, tumours were prepared and macroscopically evaluated. The apparent tumour volume was calculated using the formula, tumour volume (mm3) = (length × width2)/2. All tissues were fixed with paraformaldehyde and embedded in paraffin according a standard protocol and routinely stained with hematoxylin and eosin for histological examination. For immunohistochemical staining, sections (5.0 μm thickness) cut from paraffin blocks were mounted to glass slides and stained with the selected markers (monoclonal mouse anti human cytokeratin antibody, clone MNF 116; monoclonal mouse anti human Ki67 antigen, clone MIB-1, DAKO Deutschland GmbH, Hamburg, Deutschland; monoclonal rat anti Mouse CD31 (PECAM-1) antibody (DIA310, clone SZ31, Dianova GmbH, Hamburg, Deutschland).
The stained slides were scanned and digitally converted into virtual slides using the Hamamatsu NDP slide scanner (Hamamatsu Nanozoomer 2.HT) and its viewing platform (NDP.Viewer).
The data were analysed using SPSS 13 for Windows computer program (SPSS Inc, Chicago, Illinois, USA). Statistical analyses were performed using non-parametric Mann Whitney U test. A p value <0.05 was considered to be significant.
GPCR, G protein-coupled receptor; G protein, heterotrimeric guanyl nucleotide-binding protein; HCC, hepatocellular carcinoma; HSC, hepatic stellate cell; MAPK, mitogen-activated protein kinase; Met, hepatocyte growth factor (HGF) receptor; MMP, matrix metalloproteinase; NO, nitric oxide; PAR-AP, PAR-activating peptide; PDGFR, platelet derived growth factor receptor; RTK, receptor tyrosine kinase; Src, non receptor tyrosine kinase; uPA, urokinase-type plasminogen activator
The authors would like to thank Beate Schulze, Elke Oswald, Kathrin Schulze (Experimental Transplantation Surgery, Department of General, Visceral and Vascular Surgery), Frank Steiniger (Electron Microscopy Center), and Ivonne Ozegowski (Department of Radiology, Experimental Radiology), Jena University Hospital for the excellent technical assistance. We are very grateful to Prof. Alexander Berndt, Institute of Pathology, Jena University Hospital, for performing CD31 immunostaining. This work was supported in part by a grant from German Research Foundation (DFG; Ka 1452/10-1).
FM planned and performed PCR, IP and western blotting, immunofluorescence detection, protein profiler arrays, migration arrays and PAR2 knockdown and corrected the manuscript. HU performed transient transfections, western blotting, and proliferation assays and partly drafted and corrected the manuscript. BG planned and performed animal experiments and corrected the manuscript. KK assisted with histological and immunohistochemical tumour assessment and corrected the manuscript, PH planned and performed the peptide syntheses, MW planned and performed electron microscopic analysis, US partly drafted and corrected the manuscript, LL and SS performed experiments and corrected the manuscript, FDB and JPM designed stable PAR2 knockdown experiments and gave substantial support to conception and study design. RK conceived the study, designed the experiments, did calcium measurements and animal experiments, and drafted the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–38.View ArticlePubMedPubMed CentralGoogle Scholar
- Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100.View ArticlePubMedGoogle Scholar
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.View ArticlePubMedGoogle Scholar
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.View ArticlePubMedGoogle Scholar
- Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3:1473–92.View ArticlePubMedGoogle Scholar
- Otranto M, Sarrazy V, Bonté F, Hinz B, Gabbiani G, Desmoulière A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012;6:203–19.View ArticlePubMedPubMed CentralGoogle Scholar
- Geng ZM, Li QH, Li WZ, Zheng JB, Shah V. Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mouse model. Cell Biochem Biophys. 2014;70:337–47.View ArticlePubMedGoogle Scholar
- Zhang L, Li Y, Qiao L, Zhao Y, Wei Y. Protective effects of hepatic stellate cells against cisplatin-induced apoptosis in human hepatoma G2 cells. Int J Oncol. 2015.Google Scholar
- Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34:834–43.View ArticlePubMedGoogle Scholar
- Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff A, Hellerbrand C. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 2009;100:646–53.View ArticlePubMedGoogle Scholar
- Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol. 2015;7:165–76.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J, Wang X. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer. 2011;129:2651–61.View ArticlePubMedGoogle Scholar
- Zhao W, Zhang L, Xu Y, Zhang Z, Ren G, Tang K, Kuang P, Zhao B, Yin Z, Wang X. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab Invest. 2014;94:182–91.View ArticlePubMedGoogle Scholar
- Coulouarn C, Clément B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol. 2014;60:1306–9.View ArticlePubMedGoogle Scholar
- Lin N, Chen Z, Lu Y, Li Y, Hu K, Xu R. Role of activated hepatic stellate cells in proliferation and metastasis of hepatocellular carcinoma. Hepatol Res. 2015;45:326–36.View ArticlePubMedGoogle Scholar
- Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012;72:2533–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653–67.View ArticlePubMedGoogle Scholar
- Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim H, Choi JS, Park YN. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One. 2014;9, e105094.View ArticlePubMedPubMed CentralGoogle Scholar
- Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A. 1994;91:9208–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Ossovskaya V, Bunnett N. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84:579–621.View ArticlePubMedGoogle Scholar
- Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger T, Hollenberg M. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1–43.View ArticlePubMedGoogle Scholar
- Hollenberg M, Renaux B, Hyun E, Houle S, Vergnolle N, Saifeddine M, Ramachandran R. Derivatized 2-furoyl-LIGRLO-amide, a versatile and selective probe for proteinase-activated receptor 2: binding and visualization. J Pharmacol Exp Ther. 2008;326:453–62.View ArticlePubMedGoogle Scholar
- Ramachandran R, Hollenberg M. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol. 2008;153 Suppl 1:S263–82.PubMedGoogle Scholar
- Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69–86.View ArticlePubMedGoogle Scholar
- Grab D, Garcia-Garcia J, Nikolskaia O, Kim Y, Brown A, Pardo C, Zhang Y, Becker K, Wilson B, de A Lima AP, et al. Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis. 2009;3, e479.View ArticlePubMedPubMed CentralGoogle Scholar
- Reddy VB, Iuga AO, Shimada SG, LaMotte RH, Lerner EA. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci. 2008;28:4331–5.View ArticlePubMedPubMed CentralGoogle Scholar
- McGuire J, Saifeddine M, Triggle C, Sun K, Hollenberg M. 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. J Pharmacol Exp Ther. 2004;309:1124–31.View ArticlePubMedGoogle Scholar
- Coelho A, Ossovskaya V, Bunnett N. Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents. 2003;1:61–72.View ArticlePubMedGoogle Scholar
- Weithauser A, Rauch U. Role of protease-activated receptors for the innate immune response of the heart. Trends Cardiovasc Med. 2014;24:249–55.View ArticlePubMedGoogle Scholar
- Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927–34.View ArticlePubMedGoogle Scholar
- Ge L, Shenoy S, Lefkowitz R, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem. 2004;279:55419–24.View ArticlePubMedGoogle Scholar
- Hjortoe G, Petersen L, Albrektsen T, Sorensen B, Norby P, Mandal S, Pendurthi U, Rao L. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103:3029–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N. MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci. 2003;73:2817–29.View ArticlePubMedGoogle Scholar
- Shi X, Gangadharan B, Brass L, Ruf W, Mueller B. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004;2:395–402.PubMedGoogle Scholar
- Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, Yamada N, Nishihara T, Ohira M, Hirakawa K. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol. 2004;24:1401–6.PubMedGoogle Scholar
- Rattenholl A, Seeliger S, Buddenkotte J, Schön M, Schön M, Ständer S, Vergnolle N, Steinhoff M. Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol. 2007;127:2245–52.View ArticlePubMedGoogle Scholar
- Morris D, Ding Y, Ricks T, Gullapalli A, Wolfe B, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006;66:307–14.View ArticlePubMedGoogle Scholar
- Versteeg H, Schaffner F, Kerver M, Petersen H, Ahamed J, Felding-Habermann B, Takada Y, Mueller B, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Bocheva G, Rattenholl A, Kempkes C, Goerge T, Lin C, D’Andrea M, Ständer S, Steinhoff M. Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. J Invest Dermatol. 2009;129:1816–23.View ArticlePubMedGoogle Scholar
- Kaufmann R, Oettel C, Horn A, Halbhuber K, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer F, et al. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 2009;30:1487–96.View ArticlePubMedGoogle Scholar
- Kaufmann R, Mussbach F, Henklein P, Settmacher U. Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells. J Cancer Res Clin Oncol. 2011;137:965–73.View ArticlePubMedGoogle Scholar
- Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, Ng IO. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:179–91.View ArticlePubMedGoogle Scholar
- Chen KD, Wang CC, Tsai MC, Wu CH, Yang HJ, Chen LY, Nakano T, Goto S, Huang KT, Hu TH, et al. Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma. Cell Death Dis. 2014;5, e1244.View ArticlePubMedPubMed CentralGoogle Scholar
- Li JL, Cai WS, Shen F, Feng Z, Zhu GH, Cao J, Xu B. Protease-activated receptor-2 modulates hepatic stellate cell collagen release and apoptotic status. Arch Biochem Biophys. 2014;545:162–6.View ArticlePubMedGoogle Scholar
- Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology. 2012;55:879–87.View ArticlePubMedGoogle Scholar
- Xu L, Hui A, Albanis E, Arthur M, O’Byrne S, Blaner W, Mukherjee P, Friedman S, Eng F. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54:142–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther. 1999;288:358–70.PubMedGoogle Scholar
- Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.View ArticlePubMedGoogle Scholar
- Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.View ArticlePubMedGoogle Scholar
- Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Büchler MW. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg. 1999;177:209–15.View ArticlePubMedGoogle Scholar
- De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol. 1997;26:886–93.View ArticlePubMedGoogle Scholar
- George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A. 1999;96:12719–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006;26:8–22.View ArticlePubMedGoogle Scholar
- Presser LD, McRae S, Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. PLoS One. 2013;8, e56367.View ArticlePubMedPubMed CentralGoogle Scholar
- Zeeh F, Witte D, Gädeken T, Rauch BH, Grage-Griebenow E, Leinung N, Fromm SJ, Stölting S, Mihara K, Kaufmann R, Settmacher U, Lehnert H, Hollenberg MD, Ungefroren H: Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. Oncotarget 2016. doi: 10.18632/oncotarget.9600.Google Scholar
- Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–50.View ArticlePubMedGoogle Scholar
- Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21:437–51.View ArticlePubMedGoogle Scholar
- Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol. 2015;15:63.View ArticlePubMedPubMed CentralGoogle Scholar
- Le Clainche C, Carlier M. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev. 2008;88:489–513.View ArticlePubMedGoogle Scholar
- Kaufmann R, Hascher A, Mußbach F, Henklein P, Katenkamp K, Westermann M, Settmacher U. Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level. Histochem Cell Biol. 2012.Google Scholar
- Friedman S. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Eng FJ, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol. 2000;279:G7–11.PubMedGoogle Scholar
- Gaça MD, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol. 2002;36:362–9.View ArticlePubMedGoogle Scholar
- Lu J, Chen B, Li S, Sun Q. Tryptase inhibitor APC 366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by tryptase/protease-activated receptor 2 interactions in hepatic stellate cells. Int Immunopharmacol. 2014;20:352–7.View ArticlePubMedGoogle Scholar
- Borensztajn K, von der Thüsen JH, Peppelenbosch MP, Spek CA. The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med. 2010;14:143–53.View ArticlePubMedGoogle Scholar
- Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R, Housset C. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest. 2000;80:697–707.View ArticlePubMedGoogle Scholar
- Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003;124:147–59.View ArticlePubMedGoogle Scholar
- Robino G, Parola M, Marra F, Caligiuri A, De Franco RM, Zamara E, Bellomo G, Gentilini P, Pinzani M, Dianzani MU. Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem. 2000;275:40561–7.View ArticlePubMedGoogle Scholar
- Lee J, Kang Decker N, Chatterjee S, Yao J, Friedman S, Shah V. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol. 2005;166:1861–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Failli P, DeFRANCO RM, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P, Pinzani M. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology. 2000;119:479–92.View ArticlePubMedGoogle Scholar
- Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol. 2001;18:257–64.PubMedGoogle Scholar
- Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–41.View ArticlePubMedGoogle Scholar
- Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest. 2012;30:689–97.View ArticlePubMedGoogle Scholar
- Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15:422–30.View ArticlePubMedGoogle Scholar
- Wang J, Chen L, Li Y, Guan XY. Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS One. 2011;6, e24967.View ArticlePubMedPubMed CentralGoogle Scholar
- Mazzocca A, Giannelli G, Antonaci S. Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link? Biochim Biophys Acta. 1806;2010:74–81.Google Scholar
- Okazaki I, Inagaki Y. Novel strategies for hepatocellular carcinoma based on MMPs science. Anticancer Agents Med Chem. 2012;12:753–63.View ArticlePubMedGoogle Scholar
- Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 2008;68:7219–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Shi K, Queiroz KC, Roelofs JJ, van Noesel CJ, Richel DJ, Spek CA. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol. 2014;234:398–409.View ArticlePubMedGoogle Scholar
- Olejar T, Vetvicka D, Zadinova M, Pouckova P, Kukal J, Jezek P, Matej R. Dual role of host Par2 in a murine model of spontaneous metastatic B16 melanoma. Anticancer Res. 2014;34:3511–5.PubMedGoogle Scholar
- Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood. 2010;116:6106–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90.View ArticlePubMedGoogle Scholar
- Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, et al. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281:32095–112.View ArticlePubMedGoogle Scholar
- Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol. 2012;165:1413–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Grynkiewicz G, Poenie M, Tsien R. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–50.PubMedGoogle Scholar
- Gee K, Brown K, Chen W, Bishop-Stewart J, Gray D, Johnson I. Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium. 2000;27:97–106.View ArticlePubMedGoogle Scholar
- Nickel TJ, Kabir MH, Talreja J, Stechschulte DJ, Dileepan KN. Constitutive expression of functionally active protease-activated receptors 1 and 2 in human conjunctival epithelial cells. Mediators Inflamm. 2006;2006:61359.View ArticlePubMedPubMed CentralGoogle Scholar
- Molino M, Woolkalis MJ, Reavey-Cantwell J, Praticó D, Andrade-Gordon P, Barnathan ES, Brass LF. Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J Biol Chem. 1997;272:11133–41.View ArticlePubMedGoogle Scholar
- Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010;116:815–8.View ArticlePubMedGoogle Scholar
- Svitkina T, Bulanova E, Chaga O, Vignjevic D, Kojima S, Vasiliev J, Borisy G. Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol. 2003;409–421.Google Scholar